Clinical Trial Update: Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2) [Phase 3]

View source ↗

Summary

Phase 3 trial completion for clobetasol propionate ophthalmic nanoemulsion 0.05% in treating inflammation and pain after cataract surgery (CLOSE-2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cataract

Drugs mentioned

• Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% (clobetasol propionate)

Snippet

Sponsor: Salvat | Conditions: Cataract | Phase 3 | Status: COMPLETED | Results posted: 2022-12-22